Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Targeted therapies, particularly monoclonal antibodies (MoAbs), represent significant advancements in lymphoma treatment.
• While B-cell receptor pathway inhibitors and immune checkpoint inhibitors are key focuses, MoAbs targeting malignant cells directly are also crucial.

Purpose of the Study:

• To review the mechanisms of action, current data, and future directions of monoclonal antibodies (MoAbs) in lymphoma management.
• To highlight the impact of novel MoAb therapies, including anti-CD20 agents, antibody-drug conjugates, and bispecific antibodies.

Main Methods:

• Literature review of recent advancements in monoclonal antibody therapies for lymphoma.
• Discussion of novel dosing strategies for existing MoAbs and the development of next-generation agents.
• Analysis of emerging antibody-drug conjugates and bispecific antibodies targeting lymphoma cells.

Main Results:

• Novel dosing schedules for anti-CD20 MoAbs like rituximab may optimize efficacy in specific lymphoma subgroups.
• Next-generation anti-CD20 MoAbs show potential to surpass rituximab's efficacy.
• MoAbs targeting other B-cell antigens, antibody-drug conjugates, and bispecific antibodies demonstrate promising results.

Conclusions:

• Monoclonal antibodies continue to significantly impact lymphoma management.
• Future improvements in patient outcomes will require meticulous trial design, translational research, and combination therapies.
• Further research into novel MoAbs and synergistic combinations is essential for advancing lymphoma treatment.